|
|
Post by peppy on Jun 4, 2019 18:19:16 GMT -5
New MannKind Granted Patent Published June 4, 2019 Use of ultrarapid acting insulinAbstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. Type: Grant Filed: March 27, 2015 Date of Patent: June 4, 2019 Assignee: MannKind Corporation Inventors: Anders Hasager Boss, Richard Petrucci patents.justia.com/patent/10307464a combo? long and short? agedhippie www.lantus.comLANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. (1) |
|
|
|
Post by mango on Jun 4, 2019 18:20:32 GMT -5
Anders Boss is a listed inventor in several MannKind patents, but like aged said, it doesn't mean anything here.
There is several MannKind patents with this same title. Here is the info for this particular one & what it means:
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/US2015/022956, filed Mar. 27, 2015, which claims benefit under 35 U.S.C. § 119(e) from U.S. Provisional Patent Application Ser. No. 61/972,159, filed Mar. 28, 2014, the contents each of which is incorporated herein by reference in its entirety.
Info - U.S. National Stage (371)
A 371 application is an application which has entered the national phase of the Patent Cooperation Treaty by the fulfillment of certain requirements in a national Office, which is an authority entrusted with the granting of national or regional patents. Such an application is filed under 35 U.S.C. §371 in the United States and is referred to as a "371 application."
|
|
|
|
Post by agedhippie on Jun 4, 2019 18:34:39 GMT -5
New MannKind Granted Patent Published June 4, 2019 Use of ultrarapid acting insulinAbstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. Type: Grant Filed: March 27, 2015 Date of Patent: June 4, 2019 Assignee: MannKind Corporation Inventors: Anders Hasager Boss, Richard Petrucci patents.justia.com/patent/10307464a combo? long and short? agedhippie www.lantus.comLANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. (1) It's really nothing special. What they are doing is mimicking the use of Mix insulin where one part is Afrezza rather than RAA or Regular. The patent is specific to Afrezza and would not stop, say, Dance from using the same approach. A lot of patents are not about anything new as much as preventing people from following the same path with a known approach, in this case they are trying to shut out people from using MDI with an Afrezza clone. |
|
|
|
Post by peppy on Jun 4, 2019 18:44:11 GMT -5
a combo? long and short? agedhippie www.lantus.comLANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. (1) It's really nothing special. What they are doing is mimicking the use of Mix insulin where one part is Afrezza rather than RAA or Regular. The patent is specific to Afrezza and would not stop, say, Dance from using the same approach. A lot of patents are not about anything new as much as preventing people from following the same path with a known approach, in this case they are trying to shut out people from using MDI with an Afrezza clone. what is the benefit of that approach, do you know anyone that doses the mixes? |
|
|
|
Post by peppy on Jun 4, 2019 18:48:07 GMT -5
I guess I am just surprised, the only one thing subq is good for is a sloooowwwww uptake.
|
|
|
|
Post by agedhippie on Jun 4, 2019 19:08:53 GMT -5
It's really nothing special. What they are doing is mimicking the use of Mix insulin where one part is Afrezza rather than RAA or Regular. The patent is specific to Afrezza and would not stop, say, Dance from using the same approach. A lot of patents are not about anything new as much as preventing people from following the same path with a known approach, in this case they are trying to shut out people from using MDI with an Afrezza clone. what is the benefit of that approach, do you know anyone that doses the mixes? Sadly a lot of people still use it because it is convenient as you take the basal and bolus insulin in a single dose. It's difficult (I would say impossible but someone will have done it) to get good control on Mix. The issue is that it's a fixed ratio so if you have a carb heavy meal and need more bolus insulin you also get more basal insulin. You are getting a 70/30 split regardless of what you need. It's difficult to get good control on Mix. In the US Mix insulin is most often given to older Type 2 diabetics for compliance reasons. |
|
|
|
Post by shawnonafrezza on Jun 4, 2019 19:11:21 GMT -5
I guess I am just surprised, the only one thing subq is good for is a sloooowwwww uptake. Sometimes that's wanted. Say you eat a 10oz steak and potatoes. Hit with Afrezza for the potatoes and the lantus for the steak. |
|
|
|
Post by peppy on Jun 4, 2019 19:17:25 GMT -5
I guess I am just surprised, the only one thing subq is good for is a sloooowwwww uptake. Sometimes that's wanted. Say you eat a 10oz steak and potatoes. Hit with Afrezza for the potatoes and the lantus for the steak. shawnflynn, once again I want to state, I am glad you are here. for fun, I am going to look again at how protein/steak has the nitrogen cleaved at the liver and then it's carbon and hydrogen gets turned into glucose/or ketones. Also steak, so much fat.... that gets turned into glucose/ketones. and the time involved |
|
|
|
Post by shawnonafrezza on Jun 4, 2019 19:32:33 GMT -5
Sometimes that's wanted. Say you eat a 10oz steak and potatoes. Hit with Afrezza for the potatoes and the lantus for the steak. shawnflynn, once again I want to state, I am glad you are here. for fun, I am going to look again at how protein/steak has the nitrogen cleaved at the liver and then it's carbon and hydrogen gets turned into glucose/or ketones. Also steak, so much fat.... that gets turned into glucose/ketones. and the time involved I don’t know if gays sarcasm but it’s the honest answer. Using R or lantus for protein is a decades old thing and it’s a potentially smart move. Whether or now the patent is for that purpose or just to hold it I obviously don’t know but it does make sense. |
|
|
|
Post by peppy on Jun 4, 2019 19:41:01 GMT -5
shawnflynn, once again I want to state, I am glad you are here. for fun, I am going to look again at how protein/steak has the nitrogen cleaved at the liver and then it's carbon and hydrogen gets turned into glucose/or ketones. Also steak, so much fat.... that gets turned into glucose/ketones. and the time involved Whether or now the patent is for that purpose or just to hold it I obviously don’t know but it does make sense. ok, no, we are talking, this is the way I am. I am a foodie. I love the study of what we are doing. Plenty of people on this board prescribe to using Keto genic , low carb diets on this board. They are eating meat and what a salad, radishes, eggplant? I had never heard or considered using basal covering proteins and fats/meats/diary. I guess it makes sense. |
|
|
|
Post by sayhey24 on Jun 4, 2019 19:52:57 GMT -5
It's really nothing special. What they are doing is mimicking the use of Mix insulin where one part is Afrezza rather than RAA or Regular. The patent is specific to Afrezza and would not stop, say, Dance from using the same approach. A lot of patents are not about anything new as much as preventing people from following the same path with a known approach, in this case they are trying to shut out people from using MDI with an Afrezza clone. what is the benefit of that approach, do you know anyone that doses the mixes? Peppy - I am not sure the question you are asking. Mannkind just got a patent on various "Afrezza first Afrezza always" protocols with and without the use of Lantus. It covers both T1 and T2 use. Whats the value? Well, they have the word ultrarapid in there. I am not sure how much that is worth. What maybe of more value is now Mannkind holds the patent on what VDex is doing and going forward Health and Wellness clinics or connected care services promoting one of the patented protocols probably needs to license the protocol from Mannkind. Maybe thats worth something, maybe even a lot with future connected care services popping up. |
|
|
|
Post by agedhippie on Jun 5, 2019 11:01:36 GMT -5
what is the benefit of that approach, do you know anyone that doses the mixes? What maybe of more value is now Mannkind holds the patent on what VDex is doing and going forward Health and Wellness clinics or connected care services promoting one of the patented protocols probably needs to license the protocol from Mannkind. Maybe thats worth something, maybe even a lot with future connected care services popping up. I don't think that would work. Has there ever been an instance of a pharma charging people to administer their drug beyond the cost of the drug? That seems like it would be counter-productive. |
|
|
|
Post by shawnonafrezza on Jun 5, 2019 11:20:30 GMT -5
What maybe of more value is now Mannkind holds the patent on what VDex is doing and going forward Health and Wellness clinics or connected care services promoting one of the patented protocols probably needs to license the protocol from Mannkind. Maybe thats worth something, maybe even a lot with future connected care services popping up. I don't think that would work. Has there ever been an instance of a pharma charging people to administer their drug beyond the cost of the drug? That seems like it would be counter-productive. If there was people would be down the throats of the DIY diabetes community. Hacking pumps, mixing insulins, putting different insulins in pens they're not supposed to be in... |
|
|
|
Post by matt on Jun 5, 2019 16:49:53 GMT -5
What maybe of more value is now Mannkind holds the patent on what VDex is doing and going forward Health and Wellness clinics or connected care services promoting one of the patented protocols probably needs to license the protocol from Mannkind. Maybe thats worth something, maybe even a lot with future connected care services popping up. I don't think that would work. Has there ever been an instance of a pharma charging people to administer their drug beyond the cost of the drug? That seems like it would be counter-productive. Yes, there have been examples of that but it is a horrible business practice that doesn't work in the real world. This is a "methods" patent which restricts how a drug can be used, but the only people who can infringe on the patent are physicians. Besides the difficulty of identifying every infringer out there, bringing a lawsuit against the relatively few customers that are actually using your product is not prominently featured in the book "How to Win Friends and Influence People". What it does do is prevent competitors from using the idea in their marketing materials but even that is of questionable value as a methods patent does not prevent medical journals from describing the method. Could a Fiasp salesperson hand out copies of a medical journal describing the method? You bet. |
|
|
|
Post by mango on Jun 7, 2019 10:38:21 GMT -5
Two New International MannKind Patent Applications Published 6/6/2019 1. Delivery of Active AgentsAbstract:A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site. Applicants: MannKind Corporation Inventors: Peter Richardson Robert A. Baughman Andrea Leone-Bay Donald Costello patentscope.wipo.int/search/en/detail.jsf?docId=US243292879&recNum=2&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=11522. Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazineAbstract:The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected am inoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others. Applicants:MannKind Corp Inventors:John J. Freeman Adrienne Stamper Melissa Heitmann patentscope.wipo.int/search/en/detail.jsf?docId=US243294434&tab=NATIONALBIBLIO&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28MannKind%29&recNum=1&maxRec=1152 |
|
